Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients
- PMID: 21771874
- DOI: 10.1158/1078-0432.CCR-11-1261
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients
Abstract
Purpose: It is unknown whether the route of administration influences dendritic cell (DC)-based immunotherapy. We compared the effect of intradermal versus intranodal administration of a DC vaccine on induction of immunologic responses in melanoma patients and examined whether concomitant administration of interleukin (IL)-2 increases the efficacy of the DC vaccine.
Experimental design: HLA-A2.1(+) melanoma patients scheduled for regional lymph node dissection were vaccinated four times biweekly via intradermal or intranodal injection with 12 × 10⁶ to 17 × 10⁶ mature DCs loaded with tyrosinase and gp100 peptides together with keyhole limpet hemocyanin (KLH). Half of the patients also received low-dose IL-2 (9 MIU daily for 7 days starting 3 days after each vaccination). KLH-specific B- and T-cell responses were monitored in blood. gp100- and tyrosinase-specific T-cell responses were monitored in blood by tetramer analysis and in biopsies from delayed-type hypersensitivity (DTH) skin tests by tetramer and functional analyses with (51)Cr release assays or IFNγ release, following coculture with peptide-pulsed T2 cells or gp100- or tyrosinase-expressing tumor cells.
Results: In 19 of 43 vaccinated patients, functional tumor antigen-specific T cells could be detected. Although significantly more DCs migrated to adjacent lymph nodes upon intranodal vaccination, this was also highly variable with a complete absence of migration in 7 of 24 intranodally vaccinated patients. Intradermal vaccinations proved superior in inducing functional tumor antigen-specific T cells. Coadministration of IL-2 did not further augment the antigen-specific T-cell response but did result in higher regulatory T-cell frequencies.
Conclusion: Intradermal vaccination resulted in superior antitumor T-cell induction when compared with intranodal vaccination. No advantage of additional IL-2 treatment could be shown.
©2011 AACR.
Similar articles
-
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.Clin Cancer Res. 2003 Nov 1;9(14):5091-100. Clin Cancer Res. 2003. PMID: 14613986
-
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.J Clin Oncol. 2005 Aug 20;23(24):5779-87. doi: 10.1200/JCO.2005.06.478. J Clin Oncol. 2005. PMID: 16110035
-
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.Clin Cancer Res. 2012 Oct 1;18(19):5460-70. doi: 10.1158/1078-0432.CCR-11-3368. Epub 2012 Aug 15. Clin Cancer Res. 2012. PMID: 22896657
-
Dendritic cell gene therapy.Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3. Surg Oncol Clin N Am. 2002. PMID: 12487060 Review.
-
TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.Biol Res. 2013;46(4):431-40. doi: 10.4067/S0716-97602013000400014. Biol Res. 2013. PMID: 24510145 Review.
Cited by
-
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.Nat Commun. 2024 Feb 23;15(1):1633. doi: 10.1038/s41467-024-45357-1. Nat Commun. 2024. PMID: 38395948 Free PMC article.
-
Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy.Cancers (Basel). 2022 May 15;14(10):2438. doi: 10.3390/cancers14102438. Cancers (Basel). 2022. PMID: 35626042 Free PMC article. Review.
-
In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.Cancer Sci. 2014 Jan;105(1):9-17. doi: 10.1111/cas.12308. Epub 2013 Nov 29. Cancer Sci. 2014. PMID: 24152338 Free PMC article.
-
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets.Cancers (Basel). 2020 Jul 7;12(7):1826. doi: 10.3390/cancers12071826. Cancers (Basel). 2020. PMID: 32645977 Free PMC article. Review.
-
Lymph node targeting for immunotherapy.Immunooncol Technol. 2023 Jun 28;20:100395. doi: 10.1016/j.iotech.2023.100395. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 37719676 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials